Novo Nordisk reported DKK79.14B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Bausch Health Companies USD 2.68B 150M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Novo Nordisk DKK 12.53B 560M Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Supernus Pharmaceuticals USD 192.1M 26.6M Sep/2025